Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14.
Ann Oncol. 2022.
PMID: 35176457
Free article.
Clinical Trial.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A.
Abou-Alfa GK, et al. Among authors: lihou cf.
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
Lancet Oncol. 2020.
PMID: 32203698
Free PMC article.
Clinical Trial.
Item in Clipboard
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A.
Bekaii-Saab TS, et al. Among authors: lihou cf.
Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.
Future Oncol. 2020.
PMID: 32677452
Free PMC article.
Clinical Trial.
Item in Clipboard
Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response.
Bibeau K, Féliz L, Lihou CF, Ren H, Abou-Alfa GK.
Bibeau K, et al. Among authors: lihou cf.
JCO Precis Oncol. 2022 Apr;6:e2100414. doi: 10.1200/PO.21.00414.
JCO Precis Oncol. 2022.
PMID: 35544727
Free PMC article.
Clinical Trial.
Item in Clipboard
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
Fujiwara Y, Kuboki Y, Furukawa M, Mizuno N, Hara H, Ioka T, Ueno M, Takahashi Y, Takahashi S, Takeuchi S, Lihou C, Ji T, Tian C, Shimizu T.
Fujiwara Y, et al.
Cancer Med. 2023 May;12(9):10597-10611. doi: 10.1002/cam4.5798. Epub 2023 Mar 31.
Cancer Med. 2023.
PMID: 37000035
Free PMC article.
Clinical Trial.
Item in Clipboard
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK.
Vogel A, et al. Among authors: lihou cf.
ESMO Open. 2024 Jun 4;9(6):103488. doi: 10.1016/j.esmoop.2024.103488. Online ahead of print.
ESMO Open. 2024.
PMID: 38838500
Free article.
Item in Clipboard
Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
Lindley A, Prager G, Bitzer M, Burn TC, Lihou CF, Croft E.
Lindley A, et al. Among authors: lihou cf.
Cancer Res Treat. 2024 Feb 7. doi: 10.4143/crt.2023.1197. Online ahead of print.
Cancer Res Treat. 2024.
PMID: 38351684
Free article.
Item in Clipboard
Cite
Cite